	US 11,723,891 B2
	Drug combinations for use in the treatment of RAS-mutant cancer
Hugo Johannes Gerhardus Snippert, Utrecht (NL); Alexander Eduard Edgar Mertens, Hilversum (NL); Carla Sofia Leiria Verissimo, Utrecht (NL); and Johannes Lukas Bos, Bunnik (NL)
Assigned to UMC Utrecht Holding B.V., Utrecht (NL)
Appl. No. 17/46,810
Filed by UMC Utrecht Holding B.V., Utrecht (NL)
PCT Filed Apr. 12, 2019, PCT No. PCT/EP2019/059409 § 371(c)(1), (2) Date Oct. 12, 2020, PCT Pub. No. WO2019/197605, PCT Pub. Date Oct. 17, 2019.
Claims priority of application No. 18167004 (EP), filed on Apr. 12, 2018; and application No. 18202272 (EP), filed on Oct. 24, 2018.
Prior Publication US 2021/0379007 A1, Dec. 9, 2021
Int. Cl. A61K 31/337 (2006.01); A61P 35/00 (2006.01); A61K 31/166 (2006.01); A61K 31/197 (2006.01); A61K 31/4184 (2006.01); A61K 31/475 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/337 (2013.01) [A61K 31/166 (2013.01); A61K 31/197 (2013.01); A61K 31/4184 (2013.01); A61K 31/475 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)]

13 Claims

1. A method for treating a RAS-mutant cancer in a subject comprising administrating to the subject a combination comprising an inhibitor of the Raf-MEK-ERK pathway and at least one of:

i) an inhibitor of both EGFR and ERBB2; and,

ii) a combination of an EGFR inhibitor and an ERBB2 inhibitor,

wherein the combination comprising the inhibitor of the Raf-MEK-ERK pathway and at least one of the inhibitor of both EGFR and ERBB2 and the combination of the EGFR inhibitor and the ERBB2 inhibitor, is administered simultaneously, separately or sequentially with:

a) microtubule targeting agent; or

b) a Src inhibitor.